Marinus Pharmaceuticals focuses on developing and commercializing treatments for rare genetic epilepsies and seizure disorders. The company offers ZTALMY, an oral suspension for treating seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. ZTALMY acts at GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. Marinus is developing ganaxolone for treating genetic epilepsy disorders like PCDH19-related epilepsy and tuberous sclerosis complex. The company has license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals. It also has collaboration agreements with Orion Corporation and Tenacia Biotechnology. Marinus was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 0.1 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.4 |